Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading sharply higher by about 24% on Monday as the stock extends a breakout run that has traders focused on fresh highs and corporate updates.
- SELLAS Life Sciences shares are testing new highs. Why is SLS stock breaking out?
What Is Driving SELLAS Life Sciences Stock Higher?
The latest leg higher follows last week’s breakout after an 8-K detailed updated employment and severance agreements for senior leadership, including CEO Dr. Angelos Stergiou and CFO John Burns, converting change-of-control protections into lump-sum payouts and requiring immediate vesting of equity awards after a qualifying termination. Traders are also positioning around the upcoming Phase 3 REGAL trial results for galinpepimut S, the company’s AML immunotherapy.
The REGAL setup is tightening: the trial is now at 78 of the 80 required survival events needed to unblind final data, which is why the stock reacted so sharply when the 8-K hit and why momentum has stayed elevated into Monday’s follow-through. That “event counter” dynamic is keeping attention on SLS.
Critical Moving Averages Levels To Watch for SLS
The longer-term trend remains firmly up: SLS is trading well above its major moving averages, including the 20-day SMA ($8.84), 50-day SMA ($7.22), 100-day SMA ($5.94), and 200-day SMA ($4.17). That “stack” is also bullish (20-day SMA above the 50-day, and the 50-day above the 200-day), which typically keeps dip-buying behavior intact until price starts losing those faster trend lines.
Momentum is the main risk flag right now, with RSI at 84.05 — deep in overbought territory — suggesting the rally is stretched and more vulnerable to sharp pullbacks if buyers pause. RSI is essentially a speedometer for the move, and readings this elevated often mean demand is strong, but the stock can cool quickly without changing the bigger uptrend.
From a levels standpoint, the stock has already pushed through its prior 52-week high ($12.43), so traders often look for “breakout retests” where former highs can act as support on any dip. Practically, that puts extra focus on nearby trend support such as the 20-day SMA as the first line that bulls typically want to defend during a momentum unwind.
- Key Resistance: $12.43 — Prior 52-week high zone that can still act as a psychological pivot after a breakout.
- Key Support: $8.84 — Aligns with the 20-day SMA, a common first support area in strong uptrends.
What Does SELLAS Life Sciences Do?
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics across cancer indications. Its pipeline includes galinpepimut-S (GPS), a peptide immunotherapy targeting the WT1 antigen, and GFH009, a selective small-molecule CDK9 inhibitor.
That matters for the current tape because biotech breakouts often cluster around “event risk,” and investors are watching for Phase 3 REGAL trial results tied to GPS in AML. When a stock is already in a strong uptrend, even corporate-structure updates (like revised change-of-control and severance terms for senior leadership) can amplify speculation and keep momentum traders engaged.
SLS Stock Price Activity Update
SLS Stock Price Activity: SELLAS Life Sciences shares were up 24.70% at $15.45 at market close on Monday, according to Benzinga Pro data.
Image: Shutterstock
